Koguchi M, Suzuki Y, Tanaka S, Fukayama S, Ishihara R, Deguchi K, Oda S, Nakane Y, Fukumoto T
Section of Studies, Tokyo Clinical Research Center.
Jpn J Antibiot. 1995 Dec;48(12):1899-905.
In order to investigate antimicrobial activities of clavulanic acid/ticarcillin (CVA/TIPC) against Escherichia coli, Enterobacter spp. and Pseudomonas aeruginosa in 1992 and 1994, beta-lactamase activities were analyzed and minimum inhibitory concentrations (MICs) were determined including those of the control drugs. The results are as follows; 1. Compared to a report in 1980, the MIC distributions of CVA/TIPC against E. coli and P. aeruginosa did not show large differences. We found, however, that CVA/TIPC-resistant strains increased among Enterobacter spp. 2. Almost all of CVA/TIPC-resistant strains of Enterobacter spp. were also resistant to cephems and new quinolones, thus they were multiple drug resistant. 3. CVA/TIPC showed strong antimicrobial activities against penicillinase producing E. coli.
为了研究1992年和1994年克拉维酸/替卡西林(CVA/TIPC)对大肠杆菌、肠杆菌属和铜绿假单胞菌的抗菌活性,分析了β-内酰胺酶活性并测定了最低抑菌浓度(MIC),包括对照药物的MIC。结果如下:1. 与1980年的一份报告相比,CVA/TIPC对大肠杆菌和铜绿假单胞菌的MIC分布没有显示出很大差异。然而,我们发现肠杆菌属中对CVA/TIPC耐药的菌株有所增加。2. 几乎所有肠杆菌属对CVA/TIPC耐药的菌株也对头孢菌素和新型喹诺酮类耐药,因此它们是多重耐药的。3. CVA/TIPC对产青霉素酶的大肠杆菌显示出很强的抗菌活性。